資料搜尋諮詢服務
找不到您所需要的資料嗎?
我們能協助您找到最符合您研究需求的資訊
請撥打 +886-2-2799-3110
或透過電子郵件與我們聯絡 mi@hintoninfo.com
IHS_EWBIEEE xploreSTRATEGY ANALYTICSELSEVIERIHS_EWB_GF

頁面路徑選單

Blood Grouping Reagents Market Research Report: Forecast till 2027

  • LinkedIn
  • facebook
  • Twitter
出版日期:2022/02/10
頁  數:142頁
文件格式:PDF
價  格:
USD 4,450 (Single-User License)
USD 6,250 (Global-User License)
線上訂購或諮詢
Blood Grouping Reagents Market Research Report- Forecast till 2027


Market Dynamics

Global Blood Grouping Reagents Market size is expected to register a healthy market growth at significant CAGR of 7.74% during the forecast period to reach USD 2,642.17 million by 2027. The expanding number of blood grouping diagnostics and the rising populace has spurred the interest for robotized blood grouping gadgets. The completely robotized frameworks can perform many tests in a solitary info, further expanding usefulness and proficiency inside the specified course of events. Also, the market players are offering completely robotized blood composing gadgets with remote access highlights for upgraded checking and result approval. What's more, this hardware has explicit highlights of cylinder size and measurement acknowledgment, incorporated quality control program, arbitrary situation for tests, continuous data about the reagent and test status, and superior quality shading results, among others.
The global blood grouping reagents market is expected to register a significant was valued at USD 1,578.78 million in 2020. The market growth is attributed to the rising incidences of chronic disorders and increasing expenditure in medical research. However, concern related to accuracy and efficacy of test kits restrain the growth of the global market.
Market Segmentation
Global Blood Grouping Reagents Market is classified based on Product, Technique, end-user and Test type.
By Product the global market is divided into Consumables and Instruments. The instruments segment is further bifurcated as Fully automated and Semi-automated.
Based on Technique used the market is categorized as PCR-based and Microarray Technique, Assay-Based Techniques, Massively Parallel Sequencing Techniques, Serology, and other techniques. The Serology segment is further classified as Gel Technique, Erythrocytes Magnetised Technology (EMT), Solid-Phase Red-Cell Adherence (SPRCA), Glass Slide and Tubes, Cassette/Kit, and Others.
By Test Type the global market is segmented into Blood Group and Phenotype, Antibody Screening, Cross-matching Tests, Antibody Identification, Coombs Tests and Antigen Typing. By end-user the Global Blood Grouping Reagents Market is sectioned as Hospitals, Blood Banks, and Clinical Laboratories.

Regional Analysis
North America dominated the global blood grouping market because of the existence of major manufacturers, growing incidences of chronic diseases accelerates the need for blood transfusion and organ transplant. The key factors, for example, presence of significant makers, expanding commonness of persistent illnesses prompting the popularity for blood transfusion and organ relocate, mechanical progressions in the clinical section, and expanding mindfulness among the populace are relied upon to drive market development. Also, expanding interests in research and cooperative way to deal with work on the innovation for blood grouping in the locale is expected to build the market size over the gauge time frame.
Asia-Pacific presents rewarding open doors for players working in the blood grouping reagents market. The blood grouping reagents market in Asia-Pacific is relied upon to be the quickest developing provincial market. Expanding interest for blood banking administrations, government drives and expanding public mindfulness about blood gift are driving the business sectors development around here.
Major Players
The major players of the global blood grouping reagents market are Merck KGaA (Germany), Bio-Rad Laboratories, Inc (US), ovacyt Group (France), Beckman Coulter, Inc (US), Haemokinesis Pty Ltd (Australia), MTC Med. Produkte GmbH (Germany), DAY medical SA (Switzerland), Rapid Labs Ltd (UK), Ortho Clinical Diagnostics (US), Diagast SAS (France), Yuvraj Biobiz Incubator India Pvt (India), Tulip Diagnostics (India), and Aikang (China).
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 MARKET STRUCTURE
2.4 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING PREVALENCE OF CHRONIC DISORDERS
4.2.2 INCREASING SPENDING IN MEDICAL RESEARCH
4.3 RESTRAINT
4.3.1 CONCERNS PERTAINING TO THE EFFICIENCY AND ACCURACY OF TEST KITS
4.4 OPPORTUNITY
4.4.1 EMERGENCE OF AUTOMATED BLOOD GROUPING DEVICES
4.5 TECHNOLOGICAL DISRUPTION
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D AND DESIGNING
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES REVIEW
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 BARGAINING POWER OF BUYERS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTES
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19
5.3.1 IMPACT ON DEMAND
5.3.2 IMPACT ON SUPPLY CHAIN
5.4 VOLUME OF TESTS FOR DONATED BLOOD, BY REGION, 2020
5.5 BLOOD TRANSFUSION VOLUME, BY REGION, 2020
6 GLOBAL BLOOD GROUPING REAGENTS, BY PRODUCT
6.1 OVERVIEW
6.2 CONSUMABLES
6.3 INSTRUMENTS
6.3.1 FULLY-AUTOMATED INSTRUMENTS
6.3.2 SEMI-AUTOMATED INSTRUMENTS
7 GLOBAL BLOOD GROUPING REAGENTS, BY TECHNIQUE
7.1 OVERVIEW
7.2 PCR-BASED AND MICROARRAY TECHNIQUE
7.3 ASSAY-BASED TECHNIQUES
7.4 MASSIVELY PARALLEL SEQUENCING TECHNIQUES
7.5 SEROLOGY
7.5.1 GEL TECHNIQUE
7.5.2 EMT
7.5.3 SPRCA
7.5.4 GLASS SLIDE AND TUBES
7.5.5 CASSETTE/KIT
7.5.6 OTHER SEROLOGY
7.6 OTHER TECHNIQUES
8 GLOBAL BLOOD GROUPING REAGENTS, BY TEST TYPE
8.1 OVERVIEW
8.2 BLOOD GROUP AND PHENOTYPES
8.3 ANTIBODY SCREENING
8.4 CROSSMATCHING TESTS
8.5 ANTIBODY IDENTIFICATION
8.6 COOMBS TEST
8.7 ANTIGEN TYPING
9 GLOBAL BLOOD GROUPING REAGENTS, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 BLOOD BANKS
9.4 CLINICAL LABORATORIES
10 GLOBAL BLOOD GROUPING REAGENTS MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 UK
10.3.3 FRANCE
10.3.4 SPAIN
10.3.5 ITALY
10.3.6 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 CHINA
10.4.2 JAPAN
10.4.3 INDIA
10.4.4 SOUTH KOREA
10.4.5 AUSTRALIA
10.4.6 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
10.5.1 MIDDLE EAST
10.5.2 AFRICA
10.5.3 LATIN AMERICA
11 COMPETITIVE LANDSCAPE
11.1 COMPETITIVE OVERVIEW
11.2 MAJOR PLAYERS IN THE GLOBAL BLOOD GROUPING REAGENTS MARKET
11.3 MAJOR GROWTH STRATEGIES IN THE GLOBAL BLOOD GROUPING REAGENTS MARKET
11.4 COMPETITIVE BENCHMARKING
11.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL BLOOD GROUPING REAGENTS MARKET
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 NEW PRODUCT DEVELOPMENTS/LAUNCHES
11.6.2 COLLABORATIONS/EXPANSIONS/PARTNERSHIPS/INVESTMENTS
11.7 MAJOR PLAYERS FINANCIAL MATRIX
11.7.1 REVENUE OF MAJOR PLAYERS, 2020
11.7.2 R&D EXPENDITURE
12 COMPANY PROFILES
12.1 MERCK KGAA
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 BIO-RAD LABORATORIES, INC.
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 NOVACYT GROUP
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS/SERVICES OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 KEY STRATEGIES
12.4 BECKMAN COULTER, INC.
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 KEY STRATEGIES
12.5 HAEMOKINESIS PTY LTD
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 KEY STRATEGIES
12.6 MTC MED. PRODUKTE GMBH
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS/SERVICES OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 KEY STRATEGIES
12.7 DAY MEDICAL SA
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 KEY STRATEGIES
12.8 RAPID LABS LTD
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 KEY STRATEGIES
12.9 ORTHO CLINICAL DIAGNOSTICS
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 SWOT ANALYSIS
12.9.6 KEY STRATEGIES
12.10 DIAGAST SAS
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS/SERVICES OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIES
12.11 GRIFOLS SA
12.11.1 COMPANY OVERVIEW
12.11.2 FINANCIAL OVERVIEW
12.11.3 PRODUCTS/SERVICES OFFERED
12.11.4 KEY DEVELOPMENTS
12.11.5 SWOT ANALYSIS
12.11.6 KEY STRATEGIES
12.12 IMMUCOR, INC.
12.12.1 COMPANY OVERVIEW
12.12.2 FINANCIAL OVERVIEW
12.12.3 PRODUCTS/SERVICES OFFERED
12.12.4 KEY DEVELOPMENTS
12.12.5 SWOT ANALYSIS
12.12.6 KEY STRATEGIES
12.13 QUOTIENT LTD
12.13.1 COMPANY OVERVIEWS
12.13.2 FINANCIAL OVERVIEW
12.13.3 PRODUCTS/SERVICES OFFERED
12.13.4 KEY DEVELOPMENTS
12.13.5 SWOT ANALYSIS
12.13.6 KEY STRATEGIES
12.14 YUVRAJ BIOBIZ INCUBATOR INDIA PVT LTD
12.14.1 COMPANY OVERVIEW
12.14.2 FINANCIAL OVERVIEW
12.14.3 PRODUCTS/SERVICES OFFERED
12.14.4 KEY DEVELOPMENTS
12.14.5 KEY STRATEGIES
12.15 TULIP DIAGNOSTICS
12.15.1 COMPANY OVERVIEW
12.15.2 FINANCIAL OVERVIEW
12.15.3 PRODUCTS/SERVICES OFFERED
12.15.4 KEY DEVELOPMENTS
12.15.5 KEY STRATEGIES
12.16 AIKANG
12.16.1 COMPANY OVERVIEW
12.16.2 FINANCIAL OVERVIEW
12.16.3 PRODUCTS/SERVICES OFFERED
12.16.4 KEY DEVELOPMENTS
12.16.5 KEY STRATEGIES
12.17 INTEC
12.17.1 COMPANY OVERVIEW
12.17.2 FINANCIAL OVERVIEW
12.17.3 PRODUCTS OFFERED
12.17.4 KEY DEVELOPMENTS
12.17.5 KEY STRATEGIES
13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS
?
?
回上頁